

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pandey et al.

Serial No.: 10/613,474

Customer No. 24961

Confirm. No.: 4936

Filed: July 2, 2003

For: *Efficient Synthesis of  
Pyropheophorbide A and Its  
Derivatives*

Art Unit: 1625

Examiner: Unassigned

BEST AVAILABLE COPY

RECEIVED  
OCT 08 2003  
TECH CENTER 1600/2900  
-1 PM 3:05

TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Dear Sir:

Transmitted herewith are an Information Disclosure Statement, Forms PTO-1449 (28 pages) and cited references for filing in connection with the above-identified application.

- ☒ The Commissioner is hereby authorized to charge any fee, including any submitted herewith if the attached check(s) is in the wrong amount or otherwise improper or missing, that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,  
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:

  
Dale L. Rieger  
Registration No. 43,045

Date: October 6, 2003  
Attorney Docket No. 25886-0095  
Address all correspondence to:  
Stephanie L. Seidman, Esq.  
HELLER, EHRMAN, WHITE & McAULIFFE LLP  
4350 La Jolla Village Drive, 7th Floor  
San Diego, California 92122-1246  
Telephone: 858 450-8400  
Facsimile: 858 587-5360  
email:sseidman@HEWM.com

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Pandey et al.

Serial No.: 10/613,474

Customer No. 24961

Confirm. No.:4936

Filed: July 2, 2003

For: *Efficient Synthesis of  
Pyropheophorbide A and Its  
Derivatives*

Art Unit: 1625

Examiner: Unassigned

**RECEIVED**  
OCT 08 2003  
TECH CENTER 1600/2900  
OCT -7 11:05

**INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE  
WITH 37 C.F.R. §§ 1.97-1.98**

Commissioner for Patents,  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is filed prior to receipt of a First Office Action on the Merits of the above-captioned application. Thus, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. The Forms PTO-1449 (28 pages) and cited references are provided herewith.

**U.S.S.N. 10/613,474**  
**Pandey et al.**  
**Information Disclosur Statement**

The documents cited on the Forms PTO-1449 and supplied herewith are in the English language except for Items HV, HW, HX, HY, HZ, and IA. Items HV, HW, HX, HZ, and IA (Japanese Patent Documents No. JP2001335578, JP2002020389, JP2002325853, JP4218002, and JP6105921, respectively) are in the Japanese language and are supplied with English language equivalents (Items HO, HR, HS, HJ, and GX, respectively). Item HY (Japanese Patent Document No. JP2003146989) is in the Japanese language and is supplied with an English language Derwent abstract (Item KE). Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Office the following U.S. and international applications, which are commonly owned and/or have one or more inventors in common with the instant application.

U.S.S.N.	Filing Date	Publication No. or Issue No.	Publication or Issue Date	Docket No.
10/384,895	03/07/03			0044RI
10/385,378	03/07/03			0044BRI
09/592,150	06/12/00	6,624,187	09/23/03	0049
09/801,163	03/07/01			0050
10/351,730	01/23/03	2003-0167033	09/04/03	0052
10/211,784	08/01/02	2002-0198576	12/26/02	0054C
09/271,575	03/18/99	6,602,274	08/05/03	0055
09/905,501	07/13/01	2002-0087205	07/04/02	0055B
10/317,269	12/10/02	2003-0109813	06/12/03	0055C
10/410,700	04/08/03			0055D
09/905,777	07/13/01	2002-0127230	09/12/02	0057

**U.S.S.N. 10/613,474**  
**Pandey et al.**  
**Information Disclosure Statement**

09/905,405	07/13/01	2003-0018371	01/23/03	0060
09/386,692	08/31/99	2003-0114434	06/19/03	0061
09/760,362	01/12/01			0062
10/091,144	03/04/02			0066B
10/607,922	06/27/03			0094
09/150,821	09/11/98			CHEN0079
10/021,891	12/12/01	2003-0030342	02/13/03	CHEN0145

Int'l App. No.	Filing Date	Publication No.	Publication Date	Docket No.
PCT/US03/02303	01/23/03			0052PC
PCT/US03/20427	06/27/03			0094PC
PCT/US03/21179	07/02/03			0095PC
03010382.4	05/10/03			CHEN0188
PCT/US02/28149	11/25/02	WO03052793	06/26/03	CHEN0187

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

**U.S.S.N. 10/613,474**  
**Pandey et al.**  
**Information Disclosure Statement**

Applicant respectfully requests that the Examiner review the foregoing references and information and that they be made of record in the file history of the above-captioned application.

Respectfully submitted,  
HELLER EHRMAN WHITE & MCAULIFFE LLP

By:   
Dale L. Rieger  
Registration No. 43,045

Date: October 6, 2003  
Attorney Docket No. 25886-0095  
**Address all correspondence to:**  
Stephanie L. Seidman, Esq.  
HELLER EHRMAN WHITE & MCAULIFFE LLP  
4350 La Jolla Village Drive, 7th Floor  
San Diego, CA 92122-1246  
Telephone: (858) 450-8400  
Facsimile: 858/587-5360  
EMAIL sseidman@HEWM.com

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	A*	3	7	1	0	7	9	5	01/16/73	Higuchi <i>et al.</i>	128	260	09/29/70
	B*	3	8	1	7	8	3	7	06/18/74	Rubenstein <i>et al.</i>	195	103.5R	05/14/71
	C*	3	9	2	7	1	9	3	12/16/75	Hansen <i>et al.</i>	424	1	05/18/73
	D*	4	0	4	4	1	2	6	08/23/77	Cook <i>et al.</i>	424	243	07/09/76
	E*	4	3	2	8	2	4	5	05/04/82	Yu <i>et al.</i>	424	305	02/13/81
	F*	4	3	3	1	6	4	7	05/25/82	Goldenberg	424	1	03/03/80
	G*	4	3	4	8	3	7	6	09/07/82	Goldenberg	424	1	03/03/80
	H*	4	3	5	8	6	0	3	11/09/82	Yu	560	2	04/16/81
	I*	4	3	6	1	5	4	4	11/30/82	Goldenberg	424	1	03/03/80
	J*	4	3	6	4	9	2	3	12/21/82	Cook <i>et al.</i>	424	46	04/30/81
	K*	4	3	7	4	9	2	5	02/22/83	Litman <i>et al.</i>	435	7	02/09/81
	L*	4	4	0	9	2	3	9	10/11/83	Yu	424	305	01/21/82
	M*	4	4	1	0	5	4	5	10/18/83	Yu <i>et al.</i>	424	305	05/10/82
	N*	4	4	1	4	2	0	9	11/08/83	Cook <i>et al.</i>	424	243	06/13/77
	O*	4	4	4	4	7	4	4	04/24/84	Goldenberg	424	1.1	09/03/82
	P*	4	4	6	8	4	5	7	08/28/84	Goldenberg <i>et al.</i>	435	69	06/01/81
	Q*	4	4	7	4	8	9	3	10/02/84	Reading	436	547	07/01/81
	R*	4	4	7	9	8	9	5	10/30/84	Auditore-Hargreaves	260	112B	05/05/82
	S*	4	5	2	2	8	1	1	06/11/85	Eppstein <i>et al.</i>	514	2	07/08/82
	T*	4	6	2	4	8	4	6	11/25/86	Goldenberg	424	1.1	07/24/84
	U*	4	6	4	9	1	5	1	03/10/87	Dougherty <i>et al.</i>	514	410	05/14/84
	V*	4	8	1	8	7	0	9	04/04/89	Primus <i>et al.</i>	436	518	01/12/87

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national phase under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	W*	4	8	6	6	1	6	8	09/12/89	Dougherty <i>et al.</i>	540	145	07/24/86
	X*	4	8	8	9	1	2	9	12/26/89	Dougherty <i>et al.</i>	128	664	09/08/88
	Y*	4	9	1	6	2	2	1	04/10/90	Kumadaki <i>et al.</i>	540	145	11/04/88
	Z*	4	9	3	2	9	3	4	06/12/90	Dougherty <i>et al.</i>	604	21	08/24/88
	AA*	4	9	4	6	7	7	8	08/07/90	Ladner <i>et al.</i>	435	69.6	01/19/89
	AB*	4	9	6	8	7	1	5	11/06/90	Dougherty <i>et al.</i>	514	410	04/26/89
	AC*	5	0	0	2	9	6	2	03/26/91	Pandey <i>et al.</i>	514	410	07/20/88
	AD*	5	0	1	5	4	6	3	05/14/91	Dougherty <i>et al.</i>	424	7.1	04/26/90
	AE*	5	0	2	8	6	2	1	07/02/91	Dougherty <i>et al.</i>	514	410	05/16/89
	AF*	5	0	3	3	2	5	2	07/23/91	Carter	53	425	07/30/90
	AG*	5	0	5	2	5	5	8	10/01/91	Carter	206	439	07/27/90
	AH*	5	0	5	9	4	1	5	10/22/91	Neuwelt	424	9	02/21/89
	AI*	5	0	6	2	4	3	1	11/05/91	Potter	128	665	03/30/90
	AJ*	5	0	6	6	2	9	1	11/19/91	Stewart	606	3	04/25/90
	AK*	5	0	7	4	6	3	2	12/24/91	Potter	385	31	03/07/90
	AL*	5	0	9	3	3	4	9	03/03/92	Pandey <i>et al.</i>	514	410	10/15/90
	AM*	5	1	1	1	8	2	1	05/12/92	Potter	128	654	11/08/88
	AN*	5	1	4	5	8	6	3	09/08/92	Dougherty <i>et al.</i>	514	410	12/04/90
	AO*	5	1	7	1	7	4	1	12/15/92	Dougherty	514	185	04/21/89
	AP*	5	1	7	3	5	0	4	12/22/92	Dougherty	514	410	01/03/91
	AQ*	5	1	9	0	5	3	6	03/02/93	Wood <i>et al.</i>	606	16	02/19/92
	AR*	5	1	9	0	9	6	6	03/02/93	Dougherty <i>et al.</i>	514	410	03/02/93

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AS*	5	1	9	8	4	6	0	03/30/93	Pandey <i>et al.</i>	514	410	01/17/92
	AT*	5	2	0	5	2	9	1	04/27/93	Potter	128	654	10/07/91
	AU*	5	2	1	9	3	4	5	06/15/93	Potter	606	15	03/30/90
	AV*	5	2	2	2	7	9	5	06/29/93	Hed	362	32	12/26/91
	AW*	5	2	2	5	4	3	3	07/06/93	Dougherty <i>et al.</i>	514	410	07/02/91
	AX*	5	2	5	7	9	7	0	11/02/93	Dougherty	604	20	04/09/92
	AY*	5	2	6	3	9	2	5	11/23/93	Gilmore Jr. <i>et al.</i>	604	4	07/22/91
	AZ*	5	3	1	4	9	0	5	05/24/94	Pandey <i>et al.</i>	514	410	11/09/92
	BA*	5	3	2	3	9	0	7	06/28/94	Kalvelage	206	531	03/15/93
	BB*	5	3	4	4	9	2	8	09/06/94	Masuya <i>et al.</i>	544	37	04/14/92
	BC*	5	4	0	3	3	0	8	04/04/95	Wood <i>et al.</i>	606	17	11/24/92
	BD*	5	4	1	8	1	3	0	05/23/95	Platz <i>et al.</i>	435	2	07/13/93
	BE*	5	4	5	9	1	5	9	10/17/95	Pandey <i>et al.</i>	514	410	05/05/94
	BF*	5	4	8	2	6	9	8	01/09/96	Griffiths	424	141	04/22/93
	BG*	5	4	9	6	3	0	8	03/05/96	Brown <i>et al.</i>	606	15	12/27/93
	BH*	5	4	9	8	7	1	0	03/12/96	Pandey <i>et al.</i>	540	145	04/22/94
	BI*	5	5	0	3	6	3	7	04/02/96	Kyricos <i>et al.</i>	607	88	10/28/92
	BJ*	5	5	0	6	2	5	5	04/09/96	Smith <i>et al.</i>	514	410	12/01/93
	BK*	5	5	2	5	3	3	8	06/11/96	Goldenberg	424	178.1	08/21/92
	BL*	5	5	3	2	1	7	1	07/02/96	Motsenbocker	436	533	05/23/94
	BM*	5	5	3	8	9	4	5	07/23/96	Pallenberg <i>et al.</i>	514	6	06/17/94
	BN*	5	5	7	1	1	5	2	11/05/96	Chen <i>et al.</i>	607	92	05/26/95

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**



FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	BO*	5	5	8	0	8	9	6	12/03/96	Horwell <i>et al.</i>	514	419	05/22/95
	BP*	5	5	9	1	8	4	7	01/07/97	Pandey <i>et al.</i>	540	472	05/23/94
	BQ*	5	5	9	9	9	2	3	02/04/97	Sessler <i>et al.</i>	540	145	02/15/94
	BR*	5	6	2	2	9	8	3	04/22/97	Horwell <i>et al.</i>	514	419	05/22/95
	BS*	5	6	2	4	7	9	8	04/29/97	Yamamoto <i>et al.</i>	435	6	12/21/93
	BT*	5	6	3	1	2	8	1	05/20/97	Horwell <i>et al.</i>	514	419	04/28/94
	BU*	5	6	3	7	3	1	1	06/10/97	Pallenberg	424	434	06/29/95
	BV*	5	6	4	8	4	8	5	07/15/97	Dolphin <i>et al.</i>	540	474	10/26/94
	BW*	5	6	6	5	3	2	8	09/09/97	Horan <i>et al.</i>	424	1.17	12/01/92
	BX*	5	6	7	1	3	1	7	09/23/97	Weishaupt <i>et al.</i>	385	137	07/16/96
	BY*	5	6	8	8	4	8	6	11/18/97	Watson <i>et al.</i>	424	1.65	10/31/94
	BZ*	5	6	9	7	9	0	2	12/16/97	Goldenberg	604	49	06/01/95
	CA*	5	6	9	8	4	0	5	12/16/97	Goldenberg	435	7.5	06/01/95
	CB*	5	7	0	2	4	3	2	12/30/97	Chen <i>et al.</i>	607	88	10/03/96
	CC*	5	7	0	3	2	3	0	12/30/97	Boyle <i>et al.</i>	540	145	12/02/94
	CD*	5	7	0	9	8	7	4	01/20/98	Hanson <i>et al.</i>	424	423	06/03/96
	CE*	5	7	1	5	8	3	7	02/10/98	Chen	128	899	08/29/96
	CF*	5	7	1	6	5	9	5	02/10/98	Goldenberg	414	1.49	08/22/94
	CG*	5	7	4	1	3	1	6	04/21/98	Chen <i>et al.</i>	607	61	12/02/96
	CH*	5	7	5	9	5	4	2	06/02/98	Gurewich	424	94.64	08/05/94
	CI*	5	7	6	6	2	3	4	06/16/98	Chen <i>et al.</i>	607	92	04/16/92
	CJ*	5	7	7	0	7	3	0	06/23/98	Pandey <i>et al.</i>	540	472	03/08/96

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application published for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	CK*	5	7	7	3	9	7	7	06/30/98	Dougherty	324	429	04/18/96
	CL*	5	7	7	6	0	9	3	07/07/98	Goldenberg	604	20	04/07/92
	CM*	5	7	7	6	0	9	4	07/07/98	Goldenberg	604	20	06/01/95
	CN*	5	7	7	6	0	9	5	07/07/98	Goldenberg	604	20	06/01/95
	CO*	5	7	8	2	8	9	6	07/21/98	Chen <i>et al.</i>	607	88	01/29/97
	CP*	5	8	0	0	4	7	8	09/01/98	Chen <i>et al.</i>	607	88	03/07/96
	CQ*	5	8	1	4	0	0	8	09/29/98	Chen <i>et al.</i>	604	21	07/29/96
	CR*	5	8	2	7	1	8	6	10/27/98	Chen <i>et al.</i>	600	407	04/11/97
	CS*	5	8	3	1	0	8	8	11/03/98	Dolphin <i>et al.</i>	540	474	05/08/97
	CT*	5	8	4	0	6	7	4	11/24/98	Yatvin <i>et al.</i>	514	2	08/01/96
	CU*	5	8	6	0	9	5	7	01/19/99	Jacobsen <i>et al.</i>	604	156	02/07/97
	CV*	5	8	6	4	0	3	5	01/26/99	Pandey <i>et al.</i>	540	472	03/06/97
	CW*	5	8	6	5	8	4	0	02/02/99	Chen	607	92	10/22/97
	CX*	5	8	7	6	4	2	7	03/02/99	Chen <i>et al.</i>	607	88	01/29/97
	CY*	5	8	8	6	1	7	3	03/23/99	Hemmi <i>et al.</i>	540	472	07/30/97
	CZ*	5	9	0	0	2	5	2	05/04/99	Calanchi <i>et al.</i>	424	459	11/06/92
	DA*	5	9	2	1	2	4	4	07/13/99	Chen <i>et al.</i>	128	897	06/11/97
	DB*	5	9	4	5	7	6	2	08/31/99	Chen <i>et al.</i>	310	171	02/10/98
	DC*	5	9	4	8	4	3	3	09/07/99	Burton <i>et al.</i>	424	448	08/21/97
	DD*	5	9	5	2	3	6	6	09/14/99	Pandey <i>et al.</i>	514	410	06/22/98
	DE*	5	9	5	7	9	6	0	09/28/99	Chen <i>et al.</i>	607	92	05/05/97
	DF*	5	9	7	2	3	6	6	10/26/99	Haynes <i>et al.</i>	424	422	09/17/96

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	DG*	5	9	8	3	1	3	4	11/09/99	Ostrow	604	20	06/12/98
	DH*	5	9	8	5	3	0	7	11/16/99	Hanson <i>et al.</i>	424	423	12/02/97
	DI*	5	9	8	5	3	1	7	11/16/99	Venkateshwaran <i>et al.</i>	424	449	09/06/96
	DJ*	5	9	9	7	5	6	9	12/07/99	Chen <i>et al.</i>	607	88	01/29/97
	DK*	5	9	9	7	8	4	2	12/07/99	Chen	424	1.29	04/13/98
	DL*	6	0	0	4	5	3	4	12/21/99	Langer <i>et al.</i>	424	9.321	04/18/97
	DM*	6	0	1	0	7	1	5	01/04/00	Wick <i>et al.</i>	424	448	10/21/97
	DN*	6	0	1	5	8	9	7	01/18/00	Theodore <i>et al.</i>	540	474	05/13/96
	DO*	6	0	1	7	8	8	8	01/25/00	Pallenberg <i>et al.</i>	514	19	12/23/97
	DP*	6	0	2	2	9	6	1	02/08/00	Yamamoto <i>et al.</i>	536	24.3	01/13/97
	DQ*	6	0	2	4	9	7	5	02/15/00	D'Angelo <i>et al.</i>	424	449	11/12/96
	DR*	6	0	2	8	0	9	9	02/22/00	de Juan, Jr.	514	434	03/13/98
	DS*	6	0	3	9	9	7	5	03/21/00	Shah <i>et al.</i>	424	473	09/20/96
	DT*	6	0	4	8	7	3	6	04/11/00	Kosak	436	536	12/30/98
	DU*	6	0	5	1	2	0	7	04/18/00	Klaveness <i>et al.</i>	424	9.1	04/28/99
	DV*	6	0	5	1	7	0	2	04/18/00	Bird <i>et al.</i>	540	122	12/03/97
	DW*	6	0	6	0	0	8	2	05/09/00	Chen <i>et al.</i>	424	450	04/18/97
	DX*	6	0	7	1	4	9	5	06/06/00	Unger <i>et al.</i>	424	9.51	10/02/97
	DY*	6	0	8	0	1	6	0	06/27/00	Chen <i>et al.</i>	606	72	12/04/96
	DZ*	6	0	8	4	7	1	7	07/04/00	Wood <i>et al.</i>	359	629	08/03/99
	EA*	6	0	9	2	5	3	1	07/25/00	Chen <i>et al.</i>	128	899	06/03/99
	EB*	6	0	9	6	0	6	6	08/01/00	Chen <i>et al.</i>	607	88	09/11/98

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	EC*	6	0	9	6	2	8	9	08/01/00	Goldenberg	424	1.49	02/10/98
	ED*	6	1	0	0	8	9	3	08/08/00	Ensz <i>et al.</i>	345	420	05/23/97
	EE*	6	1	0	3	7	5	1	08/15/00	Pandey <i>et al.</i>	514	410	06/22/98
	EF*	6	1	2	0	7	5	1	09/19/00	Unger	424	9.51	09/08/97
	EG*	6	1	2	3	9	2	3	09/26/00	Unger <i>et al.</i>	424	9.52	12/18/97
	EH*	6	1	2	4	3	4	2	09/26/00	Okamoto <i>et al.</i>	514	432	06/18/97
	EI*	6	1	3	1	5	7	0	10/17/00	Schuster <i>et al.</i>	128	203.26	06/30/98
	EJ*	6	1	3	8	6	8	1	10/31/00	Chen <i>et al.</i>	128	899	10/13/97
	EK*	6	1	3	9	8	6	5	10/31/00	Friend <i>et al.</i>	424	441	10/01/97
	EL*	6	1	5	6	5	0	6	12/05/00	Yamamoto <i>et al.</i>	435	6	04/01/97
	EM*	6	1	6	2	2	1	3	12/19/00	Stewart	606	10	01/07/94
	EN*	6	1	6	7	3	0	1	12/26/00	Flower <i>et al.</i>	604	20	08/29/95
	EO*	6	1	7	6	8	4	2	01/23/01 B1	Tachibana <i>et al.</i>	604	22	09/21/98
	EP*	6	2	1	0	4	2	5	04/03/01 B1	Chen	607	88	07/08/99
	EQ*	6	2	1	7	8	6	9	04/17/01 B1	Meyer <i>et al.</i>	424	178.1	09/05/97
	ER*	6	2	3	2	2	9	5	05/15/01 B1	Kayyem <i>et al.</i>	514	44	10/12/94
	ES*	6	2	3	8	4	2	6	05/29/01 B1	Chen	607	88	07/19/99
	ET*	6	2	4	2	4	7	7	06/05/01 B1	Okamoto <i>et al.</i>	514	432	06/30/99
	EU*	6	2	5	3	8	7	2	07/03/01 B1	Neumann	181	210	11/24/98

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 35 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for a U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	EV*	6	2	5	6	5	3	3	07/03/01 B1	Yuzhakov <i>et al.</i>	604	21	06/09/99
	EW*	6	2	6	1	5	9	5	07/17/01 B1	Stanley <i>et al.</i>	424	449	02/29/00
	EX*	6	2	6	4	9	1	4	07/24/01 B1	Klaveness <i>et al.</i>	424	1.65	04/28/99
	EY*	6	2	6	7	9	8	3	07/31/01 B1	Fujii <i>et al.</i>	424	448	08/11/99
	EZ*	6	2	6	8	1	2	0	07/31/01 B1	Platz <i>et al.</i>	435	2	10/19/99
	FA*	6	2	7	1	3	5	9	08/07/01 B1	Norris <i>et al.</i>	536	23.1	04/14/99
	FB*	6	2	7	3	9	0	4	08/14/01 B1	Chen <i>et al.</i>	607	88	03/02/99
	FC*	6	2	7	4	5	5	2	08/14/01 B1	Tamarkin <i>et al.</i>	514	12	11/10/97
	FD*	6	2	8	1	6	1	1	08/28/01 B1	Chen <i>et al.</i>	310	171	04/11/00
	FE*	6	3	0	7	1	4	7	10/23/01 B1	Bird <i>et al.</i>	136	263	04/18/00
	FF*	6	3	1	6	6	5	2	11/13/01 B1	Steliou	556	42	06/06/95
	FG*	6	3	1	9	2	7	3	11/20/01 B1	Chen <i>et al.</i>	607	88	12/16/99
	FH*	6	3	1	9	4	8	8	11/20/01 B1	Licha <i>et al.</i>	424	9.6	04/09/98
	FI*	6	3	3	1	1	7	5	12/18/01 B1	Goldenberg	604	522	07/06/98
	FJ*	6	3	3	1	7	4	4	12/18/01 B1	Chen <i>et al.</i>	310	171	04/11/00

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	FK*	6	3	4	4	0	5	0	02/05/02 B1	Chen	607	88	12/21/98
	FL*	6	3	5	0	4	3	1	02/26/02 B1	Snow <i>et al.</i>	424	9.6	10/28/99
	FM*	6	3	8	7	3	5	0	05/14/02 B2	Goldenberg	424	1.57	07/08/99
	FN*	6	4	0	6	2	9	7	06/18/02 B1	Raymond <i>et al.</i>	434	15	02/18/00
	FO*	6	4	1	6	5	3	1	07/09/02 B2	Chen	607	89	06/24/98
	FP*	6	4	8	2	5	1	7	11/19/02 B1	Anderson	428	402.24	08/16/00
	FQ*	6	4	8	9	3	1	4	12/03/02 B1	Ashley <i>et al.</i>	514	183	04/03/01
	FR*	6	4	9	5	5	8	5	12/17/02 B2	Bellnier <i>et al.</i>	514	410	03/07/01
	FS*	6	4	9	8	9	4	5	12/24/02 B1	Alfheim <i>et al.</i>	600	407	11/08/99
	FT*	6	5	0	0	8	1	6	12/31/02 B1	Ekimoto <i>et al.</i>	514	185	03/12/01
	FU*	6	5	1	1	9	7	1	01/28/03 B1	Gorun	514	183	10/12/99
	FV*	6	5	1	4	9	9	5	02/04/03 B1	Zaleski <i>et al.</i>	514	332	09/25/01
	FW*	6	5	1	5	1	1	3	02/04/03 B2	Raymond <i>et al.</i>	534	15	02/18/00
	FX*	6	5	2	0	6	6	9	02/18/03 B1	Chen <i>et al.</i>	362	545	06/19/00
	FY*	6	5	2	4	5	5	2	02/25/03 B2	Klaveness <i>et al.</i>	424	1.85	02/20/01

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	FZ*	6	5	2	5	0	8	8	02/25/03 B1	Nagano <i>et al.</i>	514	452	01/03/01
	GA*	6	5	2	7	7	5	9	03/04/03 B1	Tachibana <i>et al.</i>	604	500	07/20/00
	GB*	6	5	3	4	0	4	0	03/18/03 B2	Pandey <i>et al.</i>	424	362	12/18/00
	GC*	6	5	4	0	9	8	0	04/01/03 B1	Blumenthal <i>et al.</i>	424	9.34	03/31/00
	GD*	6	5	5	4	8	5	3	04/29/03 B2	Chen	607	88	07/20/01
	GE*	6	5	5	9	3	7	4	05/06/03 B2	Lindsey <i>et al.</i>	136	263	05/10/01
	GF*	6	5	6	6	5	1	7	05/20/03 B2	Miura <i>et al.</i>	540	145	06/06/01
	GG*	6	5	6	9	8	4	6	05/27/03 B1	Scherz <i>et al.</i>	514	185	09/18/01
	GH*	6	5	7	2	8	3	9	06/03/03 B2	Sugita <i>et al.</i>	424	9.5	03/09/01
	GI*	6	5	8	0	2	2	8	06/17/03 B1	Chen <i>et al.</i>	315	185R	08/22/00
	GJ*	6	6	0	2	2	7	4	08/05/03 B1	Chen	607	88	03/18/99
	GK*	R	E	2	8	8	1	9	05/18/76	Thompson	424	243	04/16/75

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
	GL	0	0	1	5	2	9	6	03/23/00	PCT A1				
	GM	0	0	3	6	9	8	3	06/29/00	PCT A1				
	GN	0	0	4	1	7	2	5	07/20/00	PCT A2				
	GO	0	0	4	1	7	2	6	07/20/00	PCT A3				
	GP	0	0	4	1	7	2	7	07/20/00	PCT A1				
	GQ	0	0	4	1	7	6	8	07/20/00	PCT A1				
	GR	0	1	0	3	7	7	0	01/18/01	PCT A1				
	GS	0	1	0	5	3	1	6	01/25/01	PCT A1				
	GT	0	1	1	5	6	9	4	03/08/01	PCT A1				
	GU	0	1	2	0	0	5	4	03/10/84	EP B1				
	GV	0	1	4	3	8	2	5	06/21/01	PCT A1				
	GW	0	1	5	1	0	8	7	07/19/01	PCT A2				
	GX	0	1	6	1	6	0	6	11/21/85	EP B1				
	GY	0	1	7	8	2	1	6	10/18/01	PCT A1				
	GZ	0	1	7	8	4	5	8	10/18/01	PCT A1				
	HA	0	1	9	8	7	0	8	12/27/01	PCT A1				
	HB	0	2	1	7	6	9	0	02/28/02	PCT A1				
	HC	0	2	4	3	9	2	9	11/04/87	EP B1				
	HD	0	3	0	2	9	4	94	04/10/03	PCT A1				
	HE	0	3	0	5	2	7	93	06/26/03	PCT A2				
	HF	0	3	0	5	6	4	07	07/10/03	PCT A2				
	HG	0	3	0	6	1	6	96	07/31/03	PCT A2				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**



FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
	HH	0	4	2	3	1	9	5	04/24/91	EP B1				
	HI	0	4	2	5	5	6	6	05/08/91	EP B1				
	HJ	0	4	5	0	1	4	9	10/09/91	EP B1				
	HK	0	4	6	8	9	9	7	02/05/92	EP B1				
	HL	0	5	1	0	0	0	7	10/28/92	EP B1				
	HM	0	6	8	2	9	5	6	11/22/95	EP B1				
	HN	0	7	6	5	1	5	2	04/02/97	EP B1				
	HO	1	1	1	0	9	6	3	06/27/01	EP A2				
	HP	1	1	3	1	1	0	0	09/12/01	EP B1				
	HQ	1	1	4	6	0	4	6	10/17/01	EP A2				
	HR	1	1	6	4	1	3	6	12/19/01	EP A1				
	HS	1	2	3	8	6	6	6	09/11/02	EP A2				
	HT	1	2	5	6	5	8	6	11/13/02	EP A1				
	HU	1	3	3	4	7	4	8	08/13/03	EP A1				
	HV	20	01	3	3	5	5	78	04/12/01	JP				X+
	HW	20	02	2	0	3	8	9	01/23/02	JP				X+
	HX	20	02	3	2	5	8	53	11/12/02	JP				X+
	HY	20	03	1	4	6	9	89	05/21/03	JP				X*
	HZ	4	2	1	8	0	0	2	07/07/92	JP				X+
	IA	6	1	0	5	9	2	1	04/19/94	JP				X+
	IB	8	4	0	1	3	8	2	04/12/84	PCT A1				
	IC	9	0	0	0	3	9	2	01/25/90	PCT A1				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
	ID	9	0	0	0	8	9	5	02/08/90	PCT A1				
	IE	9	0	1	2	5	7	3	11/01/90	PCT A1				
	IF	9	1	1	0	4	7	4	07/25/91	PCT A1				
	IG	9	3	1	3	7	6	9	07/22/93	PCT A1				
	IH	9	4	0	9	8	5	1	05/11/94	PCT A1				
	II	9	4	2	7	5	9	4	12/08/94	PCT A1				
	IJ	9	5	0	5	2	1	4	02/23/95	PCT A1				
	IK	9	5	3	2	2	0	6	11/30/95	PCT A1				
	IL	9	5	3	5	0	8	5	12/28/95	PCT A1				
	IM	9	6	3	7	2	5	5	11/28/96	PCT A1				
	IN	9	6	3	9	1	4	4	12/12/96	PCT A1				
	IO	9	7	0	1	5	5	9	01/16/97	PCT A1				
	IP	9	7	3	2	5	2	0	09/12/97	PCT A1				
	IQ	9	7	3	2	8	8	5	09/12/97	PCT A1				
	IR	9	8	0	4	3	1	7	02/05/98	PCT A1				
	IS	9	8	0	6	4	5	6	02/19/98	PCT A1				
	IT	9	8	0	8	5	6	5	03/05/98	PCT A1				
	IU	9	8	1	4	2	4	3	04/09/98	PCT A1				
	IV	9	8	2	4	3	7	1	06/11/98	PCT A1				
	IW	9	8	2	4	5	1	0	06/11/98	PCT A1				
	IX	9	8	3	2	4	9	1	07/30/98	PCT A1				
	IY	9	8	3	2	4	9	2	07/30/98	PCT A1				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371(a) after June 30, 2003. See 37 CFR 1.491(b).

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
	IZ	9	8	3	2	4	9	3	07/30/98	PCT A1				
	JA	9	8	4	6	1	3	0	10/22/98	PCT A1				
	JB	9	8	5	0	0	3	4	11/12/98	PCT A1				
	JC	9	8	5	6	3	0	2	12/17/98	PCT A1				
	JD	9	9	1	8	8	7	9	04/22/99	PCT A1				
	JE	9	9	2	0	3	4	6	04/29/99	PCT A1				
	JF	9	9	3	9	7	6	9	08/12/99	PCT A1				
	JG	9	9	5	2	5	6	5	10/21/99	PCT A1				
	JH	9	9	5	8	1	4	9	11/18/99	PCT A1				
	JI	9	9	6	6	9	8	8	12/29/99	PCT A1				
	JJ	9	9	6	7	2	4	8	12/29/99	PCT A1				
	JK	9	9	6	7	2	4	9	12/29/99	PCT A1				

X\* = An English language Derwent abstract is provided.  
X+ = An English language equivalent is provided.

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

JL	Bellnier <i>et al.</i> , "Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients", <i>Cancer Res.</i> , <u>63</u> (8):1806-1813 (2003)
JM	Bellnier <i>et al.</i> , "Design and construction of a light-delivery system for photodynamic therapy", <i>Med. Phys.</i> , <u>26</u> (8):1552-1558 (1999)
JN	Bellnier <i>et al.</i> , "The time course of cutaneous porphyrin photosensitization in the murine ear", <i>Photochemistry and Photobiology</i> , <u>49</u> (3):369-372 (1989)
JO	Bellnier <i>et al.</i> , "Murine pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a", <i>J Photochem Photobiol B</i> , <u>20</u> (1):55-61 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	JP	Bellnier <i>et al.</i> , "The validation of a new vascular damage assay for photodynamic therapy agents", <i>Photochem Photobiol.</i> , <u>62(5)</u> :896-905 (1995)
	JQ	Bellnier <i>et al.</i> "Protection of murine foot tissue and transplantable tumor against Photofrin-II-mediated photodynamic sensitization with WR-2721", <i>Journal of Photochemistry and Photobiology B. Biology</i> <u>4</u> :219-225 (1989)
	JR	Bellnier <i>et al.</i> "An assay for the quantitation of Photofrin in tissues and fluids", <i>Photochem Photobiol.</i> <u>66(2)</u> :237-244 (1997)
	JS	Bellnier <i>et al.</i> , "Distribution and elimination of Photofrin II in mice", <i>Photochemistry and Photobiology</i> <u>50(2)</u> :221-228 (1989)
	JT	Bellnier <i>et al.</i> , "Membrane lysis in Chinese hamster ovary cells treated with hemtoporphyrin derivative plus light", <i>Photochem Photobiol.</i> <u>36(1)</u> :43-47 (1982)
	JU	Bellnier <i>et al.</i> , "A preliminary pharmacokinetic study of intravenous Photofrin in patients", <i>J Clin Laser Med Surg.</i> , <u>14(5)</u> :311-4 (1996)
	JV	Bellnier <i>et al.</i> , "Haematoporphyrin derivative photosensitization and gamma-radiation damage interaction in Chinese hamster ovary fibroblasts", <i>Int J Radiat Biol Relat Stud Phys Chem Med.</i> <u>50(4)</u> :659-664 (1986)
	JW	Bernstein <i>et al.</i> , "Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma", <i>AIDS</i> , <u>13(13)</u> :1697-1704 (1999)
	JX	Box <i>et al.</i> , "Radical ion saturation in some sulfur compounds x-irradiated at 4.2 degrees" <i>K. Radiat Res.</i> <u>51(1)</u> :10-14 (1972)
	JY	Boyle <i>et al.</i> , "Photobleaching of photofrin II as a means of eliminating skin photosensitivity", <i>Photochemistry and Photobiology</i> , <u>46(6)</u> :997-1001 (1987)
	JZ	Brasseur <i>et al.</i> , "Photodynamic activities and skin photosensitivity of the bis(dimethylhexylsiloxy)silicon 2,3-naphthalocyanine in mice", <i>Photochemistry and Photobiology</i> <u>62(6)</u> :1058-1065 (1995)
	KA	Brennan <i>et al.</i> , "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G <sub>1</sub> Fragments", <i>Science</i> , <u>229</u> : 81-83 (1985)
	KB	Bugelski <i>et al.</i> , "Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse", <i>Cancer Res.</i> , <u>41(11 Pt 1)</u> :4606-4612 (1981)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KC	Chen <i>et al.</i> , "Effect of meso-substituents on the osmium tetroxide reaction and pinacol-pinacolone rearrangement of the corresponding vic-dihydroxyporphyrins", <i>J Org Chem.</i> <u>66(11)</u> :3930-3939 (2001)
KD	Chen <i>et al.</i> , "Bacteriopurpurinimides: highly stable and potent photosensitizers for photodynamic therapy", <i>J. Med. Chem.</i> <u>45</u> :255-258 (2002)
KE	Derwent Abstract Accession No. 9432597, for Japanese Patent Application JP 2003146989 published 05/21/2003, entitled "Pyropheophorbides and their use in photodynamic therapy".
KF	Dimitroff <i>et al.</i> , "Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy", <i>Investigational New Drugs</i> , <u>17</u> :121-135 (1999)
KG	Dissous <i>et al.</i> , <i>Schistosoma Mansoni</i> Surface Antigen Defined by a Rat Monoclonal IgG2a", <i>J. Immunol.</i> <u>129</u> : 2232-2234 (1982)
KH	Doiron <i>et al.</i> , "Fluorescence bronchoscopy for detection of lung cancer", <i>Chest</i> , <u>76(1)</u> :27-32 (1979)
KI	Dougherty TJ, "Transannular peroxides as radiation sensitizers", <i>Radiat Res.</i> , <u>55(1)</u> :101-108 (1973)
KJ	Dougherty TJ, "A brief history of clinical photodynamic therapy development at Roswell Park Cancer Institute", <i>J Clin Laser Med Surg.</i> <u>14(5)</u> :219-221 (1996)
KK	Dougherty TJ, "Use of hematoporphyrin in photodynamic therapy", <i>J Photochem Photobiol B.</i> <u>8(4)</u> :439 (1991)
KL	Dougherty TJ, "Photosensitizers: therapy and detection of malignant tumors", <i>Photochemistry and Photobiology</i> <u>45(6)</u> :879-889 (1987)
KM	Dougherty TJ, "Activated dyes as antitumor agents", <i>J Natl Cancer Inst.</i> <u>52(4)</u> :1333-1336 (1974)
KN	Dougherty TJ, "Photodynamic therapy", <i>Photochem Photobiol.</i> , <u>58(6)</u> :895-900 (1993)
KO	Dougherty TJ, "Photodynamic Therapy: Part II", <i>Seminars in Surgical Oncology</i> , <u>11</u> :333-334 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the PTO's waiver from 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KP	Dougherty TJ, "Photodynamic therapy: status and potential", <i>Oncology (Huntingt)</i> . <u>3(7)</u> :67-73; Discussion 74, 77-78 (1989)
KQ	Dougherty TJ, "Photoradiation therapy for cutaneous and subcutaneous malignancies", <i>J Invest Dermatol</i> . <u>77(1)</u> :122-124 (1981)
KR	Dougherty TJ, "Photodynamic therapy (PDT) of malignant tumors", <i>CRC Critical Reviews in Oncology/Hematology</i> <u>2(2)</u> :83-116 (1984)
KS	Dougherty TJ, "Photoradiation therapy", <i>Urology</i> , <u>23(3 Suppl)</u> :61-64 (1984)
KT	Dougherty TJ, "Photosensitization of malignant tumors", <i>Seminars in Surgical Oncology</i> <u>2</u> :24-37 (1986)
KU	Dougherty TJ, "Variability in hematoporphyrin derivative preparations", <i>Cancer Res</i> . <u>42(3)</u> :1188 (1982)
KV	Dougherty TJ, "Photoradiation therapy for bronchogenic cancer", <i>Chest</i> , <u>81(3)</u> :265-266 (1982)
KW	Dougherty TJ, "Photodynamic therapy--new approaches", <i>Seminars in Surgical Oncology</i> <u>5</u> :6-16 (1989)
KX	Dougherty TJ, "Hematoporphyrin as a photosensitizer of tumors", <i>Photochem Photobiol</i> . <u>38(3)</u> :377-379 (1983)
KY	Dougherty TJ, "Photodynamic therapy", <i>Adv Exp Med Biol</i> . <u>193</u> :313-328 (1985)
KZ	Dougherty TJ, "Photodynamic therapy", <i>Clinics in Chest Medicine</i> , <u>6(2)</u> :219-236 (1985)
LA	Dougherty TJ, "An update on photodynamic therapy applications", <i>J Clin Laser Med Surg</i> . <u>20(1)</u> :3-7 (2002)
LB	Dougherty TJ, "Studies on the structure of porphyrins contained in Photofrin II" <i>Photochem Photobiol</i> . <u>46(5)</u> :569-573 (1987)
LC	Dougherty <i>et al.</i> , "Energetics and efficiency of photoinactivation of murine tumor cells containing hematoporphyrin", <i>Cancer Research</i> <u>36</u> :2330-2333 (1976)
LD	Dougherty <i>et al.</i> , "Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light", <i>Journal of the National Cancer Institute</i> , <u>55(1)</u> :115-121 (1975)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

LE	Dougherty <i>et al.</i> , "Photoradiation therapy for the treatment of malignant tumors", <i>Cancer Res.</i> <u>38(8)</u> :2628-2635 (1978)
LF	Dougherty <i>et al.</i> , "Photodynamic Therapy," <i>Journal of the National Cancer Institute</i> , <u>90(12)</u> :889-905 (1998)
LG	Dougherty TJ, "Hematoporphyrin derivative for detection and treatment of cancer", <i>J Surg Oncol.</i> <u>15(3)</u> :209-210 (1980)
LH	Dougherty <i>et al.</i> , "Photoradiation therapy--clinical and drug advances", <i>Adv Exp Med Biol.</i> <u>160</u> :3-13 (1983)
LI	Dougherty <i>et al.</i> , "Photoradiation in the treatment of recurrent breast carcinoma", <i>J Natl Cancer Inst.</i> , <u>62(2)</u> :231-237 (1979)
LJ	Dougherty <i>et al.</i> , "Cutaneous phototoxic occurrences in patients receiving Photofrin", <i>Lasers Surg Med.</i> <u>10(5)</u> :485-488 (1990)
LK	Dougherty <i>et al.</i> , "Interstitial photoradiation therapy for primary solid tumors in pet cats and dogs", <i>Cancer Res.</i> <u>41(2)</u> :401-404 (1981)
LL	Dougherty, "Photodynamic therapy in gastrointestinal cancer", <i>Lasers in Surgery and Medicine</i> <u>12</u> :114 (1992)
LM	Dougherty <i>et al.</i> , "Characterization of intra-tumoral porphyrin following injection of hematoporphyrin derivative or its purified component", <i>Photochemistry and Photobiology</i> , <u>46(1)</u> :67-70 (1987)
LN	Dougherty <i>et al.</i> , "The role of the peripheral benzodiazepine receptor in photodynamic activity of certain pyropheophorbide ether photosensitizers: albumin site II as a surrogate marker for activity", <i>Photochem Photobiol.</i> , <u>76(1)</u> :91-97 (2002)
LO	Dougherty TJ, "An overview of the status of photoradiation therapy", <i>Prog Clin Biol Res.</i> <u>170</u> :75-87 (1984)
LP	Dougherty <i>et al.</i> , "Photodynamic therapy", <i>Eur J Cancer.</i> <u>28A(10)</u> :1734-1742 (1992)
LQ	Dougherty <i>et al.</i> , "The structure of the active component of hematoporphyrin derivative", <i>Prog Clin Biol Res.</i> , <u>170</u> :301-314 (1984)
LR	Dougherty <i>et al.</i> , "Of what value is a highly absorbing photosensitizer in PDT?" <i>J Photochem Photobiol B.</i> , <u>8(2)</u> :223-225 (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

LS	Douglass <i>et al.</i> , "Intra-abdominal applications of hematoporphyrin photoradiation therapy", <i>Adv Exp Med Biol.</i> , <u>160</u> :15-21 (1983)
LT	Farrell <i>et al.</i> , "A diffusion theory model of spatially resolved, steady-state diffuse reflectance for the noninvasive determination of tissue optical properties <i>in vivo</i> ", <i>Med. Phys.</i> , <u>19</u> (4):879-888 (1992)
LU	Fingar <i>et al.</i> , "Drug and light dose dependence of photodynamic therapy: a study of tumor cell clonogenicity and histologic changes", <i>Photochem Photobiol.</i> , <u>45</u> (5):643-650 (1987)
LV	Flock <i>et al.</i> , "Monte Carlo Modeling of Light Propagation in Highly Scattering Tissues - I: Model Predictions and Comparison with Diffusion Theory," <i>IEEE Transactions on Biomedical Engineering</i> , <u>36</u> (12):1162-1168 (1989)
LW	Flock <i>et al.</i> , "Monte Carlo Modeling of Light Propagation in Highly Scattering Tissues - II: Comparison with Measurements in Phantoms," <i>IEEE Transactions on Biomedical Engineering</i> , <u>36</u> (12):1169-1173 (1989)
LX	Fukuzumi <i>et al.</i> , "Photochemical and electrochemical properties of zinc chlorin-C60 dyad as compared to corresponding free-base chlorin-C60, free-base porphyrin-C60, and zinc porphyrin-C60 dyads", <i>J Am Chem Soc.</i> , <u>123</u> (43):10676-10683 (2001)
LY	Glennie <i>et al.</i> , "Preparation and Performance of Bispecific F(ab' $\gamma$ ) <sub>2</sub> Antibody Containing Thioether-Linked Fab' $\gamma$ Fragments", <i>J. Immunol.</i> , <u>139</u> :2367-2375 (1987)
LZ	Gomer CJ <i>et al.</i> , "Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue", <i>Cancer Res.</i> <u>39</u> (1):146-151 (1979)
MA	Graham <i>et al.</i> , "Structure-activity relationship of new octaethylporphyrin-based benzochlorins as photosensitizers for photodynamic therapy", <i>Photochem Photobiol.</i> <u>77</u> (5):561-566 (2003)
MB	Gryshuk <i>et al.</i> , "A first comparative study of purpurinimide-based fluorinated vs. nonfluorinated photosensitizers for photodynamic therapy", <i>Photochem Photobiol.</i> , <u>76</u> (5):555-559 (2002)
MC	Gryzch <i>et al.</i> , "In Vitro and In Vivo Effector Function of Rat IgG2a Monoclonal Anti-S. Masoni Antibodies", <i>J. Immunol.</i> <u>129</u> : 2739-2743 (1982)
MD	Henderson <i>et al.</i> , "Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy", <i>Cancer Res.</i> , <u>45</u> (2):572-576 (1985)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**



FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

ME	Henderson <i>et al.</i> , "Interaction of photodynamic therapy and hyperthermia: tumor response and cell survival studies after treatment of mice in vivo", <i>Cancer Res.</i> , <u>45</u> (12 Pt 1):6071-6077 (1985)
MF	Henderson <i>et al.</i> , "Bacteriochlorophyll- <i>a</i> as photosensitizer for photodynamic treatment of transplantable murine tumors", <i>J. Photochem. Photobiol. B: Biol.</i> <u>10</u> :303-313 (1991)
MG	Henderson <i>et al.</i> , "An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy", <i>Cancer Res.</i> <u>57</u> (18):4000-4007 (1997)
MH	Henderson <i>et al.</i> , "How does photodynamic therapy work?" <i>Photochem Photobiol.</i> <u>55</u> (1):145-157 (1992)
MI	Henderson <i>et al.</i> , "Aspects of the cellular uptake and retention of hematoporphyrin derivative and their correlation with the biological response to PRT in vitro", <i>Adv Exp Med Biol.</i> , <u>160</u> :129-38 (1983)
MJ	Henderson <i>et al.</i> , "Studies on the mechanism of tumor destruction by photoradiation therapy", <i>Prog Clin Biol Res.</i> <u>170</u> :601-612 (1984)
MK	Herrera-Ornelas <i>et al.</i> , "Photodynamic therapy in patients with colorectal cancer", <i>Cancer</i> , <u>57</u> (3):677-684 (1986)
ML	Ho <i>et al.</i> , "Some components of the tumor-localizing fraction of hematoporphyrin derivative", <i>Photochemistry and Photobiology</i> , <u>52</u> (6):1085-1088 (1990)
MM	Ho <i>et al.</i> , "Carbon-14 labeling and biological activity of the tumor-localizing derivative of hematoporphyrin", <i>Photochem Photobiol.</i> <u>48</u> (4):445-449 (1988)
MN	Ho <i>et al.</i> , "Activity and physicochemical properties of Photofrin", <i>Photochem Photobiol.</i> <u>54</u> (1):83-87 (1991)
MO	IUPAC-IUB Commission on Biochemical Nomenclature (see, <i>Biochem.</i> 11: 942-944 (1972))
MP	Karpovsky <i>et al.</i> , "Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fcγ", <i>J. Exp. Med.</i> <u>160</u> :1686 (1984)
MQ	Kasper <i>et al.</i> , "Isolation and Characterization of A Monoclonal Antibody-Resistant Antigenic Mutant of <i>Toxoplasma Gondii</i> ", <i>J. Immunol.</i> <u>129</u> : 1694-1699 (1982)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MR	Kessel <i>et al.</i> , "Photosensitization with bacteriochlorins", <i>Photochem Photobiol.</i> , <u>58(2)</u> :200-203 (1993)
MS	Kessel <i>et al.</i> , "Photosensitization by diporphyrins joined via methylene bridges", <i>Photochemistry and Photobiology</i> <u>48(6)</u> :741-744 (1988)
MT	Kessel <i>et al.</i> , "Photosensitization by synthetic diporphyrins and dichlorins <i>in vivo</i> and <i>in vitro</i> ", <i>Photochemistry and Photobiology</i> <u>53(4)</u> :475-479 (1991)
MU	Khan <i>et al.</i> , "An evaluation of photodynamic therapy in the management of cutaneous metastases of breast cancer", <i>Eur J Cancer</i> . <u>29A(12)</u> :1686-1690 (1993)
MV	Kher <i>et al.</i> , "Mechano and thermoluminescence of gamma-irradiated CaSO <sub>4</sub> :Dy phosphor.", <i>Radiat Prot Dosimetry</i> . <u>100(1-4)</u> :281-284 (2002)
MW	Kozyrev <i>et al.</i> , "Thermolysis of vic-dihydroxybacteriochlorins: a new approach for the synthesis of chlorin-chlorin and chlorin-porphyrin dimers", <i>Org Lett.</i> <u>1(8)</u> :1193-1196 (1999)
MX	Lele <i>et al.</i> , "Photodynamic therapy in gynecologic malignancies", <i>Gynecol Oncol.</i> <u>34(3)</u> :350-352 (1989)
MY	Li <i>et al.</i> , "A novel synthetic route to fused propenochlorin and benzochlorin photodynamic therapy probes", <i>Chem Commun (Camb)</i> . <u>(11)</u> :1172-1173 (2002)
MZ	Li <i>et al.</i> , "Thermolysis of vic-dihydroxybacteriochlorins: effect of the nature of substrates in directing the formation of chlorin-chlorin dimers with fixed and flexible orientations and their preliminary <i>in vitro</i> photosensitizing efficacy", <i>J Org Chem.</i> <u>68(10)</u> :3762-3772 (2003)
NA	Li <i>et al.</i> , "A simple and efficient approach for the synthesis of fluorinated and nonfluorinated octaethylporphyrin-based benzochlorins with variable lipophilicity, their <i>in vivo</i> tumor uptake, and the preliminary <i>in vitro</i> photosensitizing efficacy", <i>J Org Chem.</i> <u>66(4)</u> :1316-1325 (2001)
NB	Liu, MA <i>et al.</i> , "Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes", <i>Proc. Natl. Acad. Sci. USA</i> <u>82</u> :8648-8652 (1985)
NC	Lobel <i>et al.</i> , "2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) in a nude rat glioma model: implications for photodynamic therapy", <i>Lasers Surg Med.</i> <u>29(5)</u> :397-405 (2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

ND	MacDonald <i>et al.</i> , "Subcellular localization patterns and their relationship to photodynamic activity of pyropheophorbide-a derivatives", <i>Photochem Photobiol.</i> <u>70(5)</u> :789-797 (1999)
NE	Mang <i>et al.</i> , "Photobleaching of porphyrins used in photodynamic therapy and implications for therapy", <i>Photochemistry and Photobiology</i> , <u>45(4)</u> :501-506 (1987)
NF	Mang <i>et al.</i> , "Time and sequence dependent influence of in vitro photodynamic therapy (PDT) survival by hyperthermia", <i>Photochem Photobiol.</i> , <u>42(5)</u> :533-540 (1985)
NG	Mang <i>et al.</i> , "Fluorescence detection of tumors. Early diagnosis of microscopic lesions in preclinical studies", <i>Cancer</i> <u>71(1)</u> :269-276 (1993)
NH	Merrifield <i>et al.</i> , "Design and synthesis of antimicrobial peptides", <i>Ciba Foundation Symposium</i> , <u>186</u> :5-20 (1994)
NI	Mettath <i>et al.</i> , "DNA interaction and photocleavage properties of porphyrins containing cationic substituents at the peripheral position" <i>Bioconjugate Chem.</i> , <u>10</u> :94-102 (1999)
NJ	Mettath <i>et al.</i> , "Effect of substituents in directing the formation of benzochlorins and isobacteriochlorins in porphyrin and chlorin systems", <i>Organic Letters</i> <u>1(12)</u> :1961-1964 (1999)
NK	Milstein <i>et al.</i> , "Hybrid hybridomas and the production of bi-specific monoclonal antibodies", <i>Immunol. Today</i> <u>5</u> :299-305 (1984)
NL	Moesta <i>et al.</i> , "Protoporphyrin IX occurs naturally in colorectal cancers and their metastases" <i>Cancer Research</i> , <u>61</u> :991-999 (2001)
NM	Morgan <i>et al.</i> , "Comparison of photodynamic targets in a carcinoma cell line and its mitochondrial DNA-deficient derivative", <i>Photochemistry and Photobiology</i> , <u>71(6)</u> :747-757 (2000)
NN	Morrison and Boyd, <i>Organic Chemistry</i> , (5th Ed., 1987), Chapter 13, entitled "Aromaticity," pages 477-497
NO	Moskal <i>et al.</i> , "Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up", <i>Ann Thorac Surg.</i> , <u>66</u> :1128-1133 (1998)
NP	Nambisan <i>et al.</i> , "Intraoperative photodynamic therapy for retroperitoneal sarcomas", <i>Cancer</i> , <u>61(6)</u> :1248-1252 (1988)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

NQ	Niedre <i>et al.</i> , "Direct Near-infrared Luminescence Detection of Singlet Oxygen Generated by Photodynamic Therapy in Cell <i>In Vitro</i> and Tissues <i>In Vivo</i> ", <i>Photochemistry and Photobiology</i> , <u>75(4)</u> :382-391 (2002)
NR	Nogrady, Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392 (1985)
NS	North <i>et al.</i> "Viral Inactivation in Blood and Red Cell Concentrates with Benzoporphyrin Derivative", <i>Blood Cells</i> <u>18</u> :129-40 (1992)
NT	Nseyo <i>et al.</i> , "Study of factors mediating effect of photodynamic therapy on bladder in canine bladder model", <i>Urology</i> , <u>32(1)</u> :41-45 (1988)
NU	Nseyo <i>et al.</i> , "Whole bladder photodynamic therapy for transitional cell carcinoma of bladder", <i>Urology</i> , <u>26(3)</u> :274-280 (1985)
NV	Nseyo <i>et al.</i> , "Photodynamic therapy in the management of resistant lower urinary tract carcinoma", <i>Cancer</i> <u>60</u> :3113-3119 (1987)
NW	Nseyo <i>et al.</i> , "Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience", <i>Journal of Clinical Laser Medicine Surgery</i> , <u>16(1)</u> :61-68 (1998)
NX	Nseyo <i>et al.</i> , "Dihematoporphyrin ether clearance in primate bladders", <i>The Journal of Urology</i> , <u>136</u> :1363-1366 (1986)
NY	Nseyo <i>et al.</i> , "Experimental photodynamic treatment of canine bladder", <i>J Urol.</i> , <u>133(2)</u> :311-315 (1985)
NZ	Paajanen <i>et al.</i> , "Proton Relaxation Enhancement of Albumin, Immunoglobulin G, and Fibrinogen Labeled with Gd-DTPA", <i>Magn. Reson. Med</i> <u>13</u> : 38-43 (1990)
OA	Pandey <i>et al.</i> , "Synthesis and photosensitizing activity of a di-porphyrin ether", <i>Chemical Abstracts</i> , <u>109</u> :320 (1988)
OB	Pandey <i>et al.</i> , "Synthesis, photophysical properties, <i>in vivo</i> photosensitizing efficacy, and human serum albumin binding properties of some novel bacteriochlorins", <i>J. Med. Chem.</i> <u>40(17)</u> :2770-2779 (1997)
OC	Pandey <i>et al.</i> , "Chlorin and porphyrin derivatives as potential photosensitizers in photodynamic therapy", <i>Photochemistry and Photobiology</i> <u>53(1)</u> :65-72 (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

OD	Pandey <i>et al.</i> , "Syntheses and photosensitizing activity of porphyrins joined with ester linkages", <i>Cancer Research</i> <u>49</u> :2042-2047 (1989)
OE	Pandey <i>et al.</i> , "Evaluation of new benzoporphyrin derivatives with enhanced PDT efficacy", <i>Photochemistry and Photobiology</i> <u>62</u> (4):764-768 (1995)
OF	Pandey <i>et al.</i> , "Alkyl ether analogs of chlorophyll-a derivatives: Part 1. Synthesis, photophysical properties and photodynamic efficacy", <i>Photochemistry and Photobiology</i> <u>64</u> (1):194-204 (1996)
OG	Pandey <i>et al.</i> , "Porphyrin dimers as photosensitizers in photodynamic therapy", <i>J. Med. Chem.</i> <u>33</u> :2032-2038 (1990)
OH	Pandey <i>et al.</i> , "Fast atom bombardment mass spectral analyses of Photofrin II and its synthetic analogs", <i>Biomedical and Environmental Mass Spectrometry</i> <u>19</u> :405-414 (1990)
OI	Pandey <i>et al.</i> , "Comparative <i>in vivo</i> sensitizing efficacy of porphyrin and chlorin dimers joined with ester, ether, carbon-carbon or amide bonds" <i>Journal of Molecular Recognition</i> <u>9</u> :118-122 (1996)
OJ	Pierce Chemical Co. catalog, pages O-90 to O-110 (1995, Pierce Chemical Co., 3747 N. Meridian Rd., Rockford Ill., 61105, U.S.A.),
OK	Polin, R.A. "Monoclonal Antibodies Against Microorganisms", <i>Eur. J. Clin. Microbiol.</i> , <u>3</u> (5): 387-398 (1984)
OL	Potter <i>et al.</i> , "The theory of photodynamic therapy dosimetry: consequences of photo-destruction of sensitizer", <i>Photochemistry and Photobiology</i> <u>46</u> (1):97-101 (1987)
OM	Potter <i>et al.</i> , "Photofrin II levels by <i>in vivo</i> fluorescence photometry", <i>Prog Clin Biol Res.</i> <u>170</u> :177-186 (1984)
ON	Potter <i>et al.</i> , "Parabolic quantitative structure-activity relationships and photodynamic therapy: application of a three-compartment model with clearance to the <i>in vivo</i> quantitative structure-activity relationships of a congeneric series of pyropheophorbide derivatives used as photosensitizers for photodynamic therapy", <i>Photochemistry and Photobiology</i> <u>70</u> (5):781-788 (1999)
OO	Prakash, G.K.S. and A.K. Yudin, "Perfluoroalkylation with Organosilicon Reagents", <i>Chem Rev.</i> , <u>97</u> :757-786 (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474 *	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

OP	Pykett, "NMR Imaging in Medicine", <i>Scientific American</i> <u>246</u> : 78 (1982)
OQ	Rakestraw, <i>et al.</i> , "Antibody-targeted photolysis: <i>In vitro</i> studies with Sn(IV) chlorin e6 covalently bound to monoclonal antibodies using a modified dextran carrier", <i>Proc. Natl. Acad. Sci. USA</i> <u>87</u> : 4217-4221 (1990)
OR	Ris <i>et al.</i> , "Absence of rhodamine 123-photochemotoxicity in human tumor xenografts", <i>Lasers Surg Med.</i> <u>13</u> (1):40-44 (1993)
OS	Roy <i>et al.</i> , "Ceramic-Based Nanoparticles Entrapping Water-Insoluble Photosensitizing Anticancer Drugs: A Novel Drug-Carrier System for Photodynamic Therapy", <i>J Am Chem Soc.</i> <u>125</u> (26):7860-7865 (2003)
OT	Runfola <i>et al.</i> , "Photodynamic therapy for residual neoplasms of the perianal skin", <i>Dis Colon Rectum.</i> <u>43</u> (4):499-502 (2000)
OU	Runge <i>et al.</i> , "Paramagnetic Agents for Contrast-Enhanced NMR Imaging: A Review", <i>Am. J. Radiol.</i> <u>141</u> : 1209 (1983)
OV	Rungta <i>et al.</i> , "Purpurinimides as photosensitizers: effect of the presence and position of the substituents in the <i>in vivo</i> photodynamic efficacy", <i>Bioorg Med Chem Lett.</i> <u>10</u> (13):1463-1466 (2000)
OW	Schuh <i>et al.</i> , "Photodynamic therapy for palliation of locally recurrent breast carcinoma", <i>Journal of Clinical Oncology</i> <u>5</u> (11):1766-1770 (1987)
OX	Senge <i>et al.</i> , "Comparative Analysis of the Conformations of Symmetrically and Asymmetrically Deca- and Undecasubstituted Porphyrins Bearing Meso-Alkyl or -Aryl Groups", <i>Inorg. Chem.</i> , <u>36</u> :1149-1163 (1997)
OY	Sery <i>et al.</i> , "Photoradiation of rabbit ocular malignant melanoma sensitized with hematoporphyrin derivative", <i>Curr Eye Res.</i> <u>3</u> (4):519-528 (1984)
OZ	Sharman <i>et al.</i> , "Photodynamic therapeutics: basic principles and clinical applications", <i>Curr. Trends Drug Discovery Today</i> <u>4</u> , 507 (1999)
PA	Siegel <i>et al.</i> , "Comparative mass spectrometric analyses of Photofrin oligomers by fast atom bombardment mass spectrometry, UV and IR matrix-assisted laser desorption/ionization mass spectrometry, electrospray ionization mass spectrometry and laser desorption/jet-cooling photoionization mass spectrometry", <i>J Mass Spectrom.</i> <u>34</u> (6):661-669 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

PB	Simpson <i>et al.</i> , "Isolation and partial characterization of the tegumental outer membrane of adult <i>Schistosoma mansoni</i> , <i>Parasitology</i> <u>83</u> : 163-177 (1981)
PC	Singh <i>et al.</i> , "Thiocarbamate linkage as internucleoside bond", <i>Indian J Biochem Biophys.</i> <u>33</u> (5):425-427 (1996)
PD	Smith <i>et al.</i> , "Passive immunization of mice against <i>Schistosoma mansoni</i> with an IgM monoclonal antibody", <i>Parasitology</i> <u>84</u> : 83-91 (1982)
PE	Smith, <i>et al.</i> , "Meso Substitution of Chlorophyll Derivatives: Direct Route for Transformation of Bacteriopheophorbides <i>d</i> into Bacteriopheophorbides <i>c</i> ", <i>J. Am. Chem. Soc.</i> <u>107</u> : 4946-4954 (1985)
PF	Svaasand <i>et al.</i> , "Temperature rise during photoradiation therapy of malignant tumors", <i>Med Phys.</i> <u>10</u> (1):10-17 (1983)
PG	Takita <i>et al.</i> , "Intracavitary photodynamic therapy for malignant pleural mesothelioma", <i>Semin Surg Oncol.</i> <u>11</u> :368-371 (1995)
PH	Takita <i>et al.</i> , "Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study", <i>Ann Thorac Surg.</i> <u>58</u> (4):995-998 (1994)
PI	Tsuchida <i>et al.</i> , "Correlation between site II-specific human serum albumin (HSA) binding affinity and murine <i>in vivo</i> photosensitizing efficacy of some Photofrin components", <i>Photochemistry and Photobiology</i> <u>66</u> (2):224-228 (1997)
PJ	Umemura <i>et al.</i> , "Recent advances in sonodynamic approach to cancer therapy", <i>Ultrasonics Sonochemistry</i> <u>3</u> : S187-S191 (1996)
PK	Van Lier, J.E. "Photosensitization: Reaction Pathways", <i>Photobiological Techniques</i> <u>216</u> : 85-98 (1991)
PL	Vincent <i>et al.</i> , "Photoradiation therapy in advanced carcinoma of the trachea and bronchus", <i>Chest</i> , <u>85</u> (1):29-33 (1984)
PM	Vincent <i>et al.</i> , "Hematoporphyrin derivative in the diagnosis and treatment of lung cancer", <i>Adv Exp Med Biol.</i> <u>160</u> :41-46 (1983)
PN	Waldow <i>et al.</i> , "Interaction of hyperthermia and photoradiation therapy" <i>Radiat Res.</i> <u>97</u> (2):380-385 (1984)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474	CONFIRM NO. 4936
	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

PO	Waldow <i>et al.</i> , "Potentiation of photodynamic therapy by heat: effect of sequence and time interval between treatments in vivo", <i>Lasers Surg Med.</i> <u>5(2)</u> :83-94 (1985)
PP	Waldow <i>et al.</i> , "Enhanced tumor control following sequential treatments of photodynamic therapy(PDT) and localized microwave hyperthermia in vivo", <i>Lasers Surg Med.</i> <u>4(1)</u> :79-85 (1984)
PQ	Waldow <i>et al.</i> , "Hyperthermic potentiation of photodynamic therapy employing Photofrin I and II: comparison of results using three animal tumor models", <i>Lasers Surg Med.</i> <u>7(1)</u> :12-22 (1987)
PR	Weishaupt <i>et al.</i> , "Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor", <i>Cancer Res.</i> , <u>36(7 PT 1)</u> :2326-2329 (1976)
PS	Wilson <i>et al.</i> , "The physics of photodynamic therapy," <i>Phys. Med. Biol.</i> , <u>31(4)</u> :327-360 (1986)
PT	Wilson <i>et al.</i> , "Photodynamic therapy for the treatment of basal cell carcinoma", <i>Arch Dermatol.</i> <u>128</u> :1597-1601 (1992)
PU	Wood <i>et al.</i> , "A beam-splitting device for use with fiber-coupled laser light sources for photodynamic therapy", <i>Photochem Photobiol.</i> , <u>76(6)</u> :683-685 (2002)
PV	Yoshida <i>et al.</i> , "Hybridoma Produces Protective Antibodies Directed Against the Sporozoite Stage of Malaria Parasite", <i>Science</i> , <u>207</u> :71-73 (1980)
PW	Yumita <i>et al.</i> , "Sonodynamically induced antitumor effect of gallium-porphyrin complex by focused ultrasound on experimental kidney tumor <i>Cancer Letters</i> <u>1,2</u> : 79-86 (1997)
PX	Yumita <i>et al.</i> , "The Combination Treatment of Ultrasound and Antitumor Drugs on Yoshida Sarcoma", <i>Japan J. Hyperthermic Oncology</i> <u>3(2)</u> :175-182 (1987)
PY	Zheng <i>et al.</i> , "A Simple and Short Synthesis of Divinyl Chlorophyll Derivatives", <i>J Org Chem.</i> <u>64</u> :3751-3754 (1999)
PZ	Zheng <i>et al.</i> , "Synthesis of beta-galactose-conjugated chlorins derived by enyne metathesis as galectin-specific photosensitizers for photodynamic therapy", <i>J Org Chem.</i> <u>66(26)</u> :8709-8716 (2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**



FORM PTO-1449	ATTY. DOCKET NO. 25886-0095	SERIAL NO. 10/613,474*	CONFIRM NO. 4936
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Pandey <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE July 2, 2003	GROUP 1625	

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

QA	Zheng <i>et al.</i> , "Synthesis, photophysical properties, tumor uptake, and preliminary in vivo photosensitizing efficacy of a homologous series of 3-(1'-alkyloxy)ethyl-3-devinylpurpurin-18- <i>N</i> -alkylimides with variable lipophilicity", <i>J Med Chem.</i> <u>44</u> :1540-1559 (2001)
QB	Zheng <i>et al.</i> , "Photosensitizers related to purpurin-18- <i>N</i> -alkylimides: a comparative in vivo tumoricidal ability of ester versus amide functionalities", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , <u>10</u> :123-127 (2000)
QC	Zheng <i>et al.</i> , "Wittig reactions on photoporphyrin IX: new synthetic models for the special pair of the photosynthetic reaction center", <i>J Org Chem.</i> <u>65</u> (2):543-557 (2000)
QD	Zodda <i>et al.</i> , "Monoclonal Antibody-Mediated Protection against <i>Schistosoma mansoni</i> Infection in Mice, <i>J. Immunol.</i> <u>129</u> : 2326-2328 (1982)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES**